# Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

> **NCT05805072** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed/Refractory AML

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Homoharringtonine
- **DRUG:** Cytarabine
- **DRUG:** Aclacinomycin
- **DRUG:** Granulocyte Colony-Stimulating Factor
- **DRUG:** Decitabine
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT05805072
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05805072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05805072, "Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05805072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*